# BeOne Medicines Ltd.: overview

ONC · Nasdaq · CIK 1651308 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/onc.md) · [Financials](/companies/onc/financials.md) · [Filings](/companies/onc/filings.md) · [Insiders](/companies/onc/insiders.md)

Latest reported revenue: [$1.71bn](/filings/0001628280-26-052878.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-052878).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,002](/filings/0001628280-25-049824.md) | [1,128 d](/filings/0001628280-26-011946.md) | [1,117](/filings/0001628280-26-030867.md) | [1,315](/filings/0001628280-26-052878.md) | [1,412](/filings/0001628280-25-049824.md) | [1,498 d](/filings/0001628280-26-011946.md) | [1,513](/filings/0001628280-26-030867.md) | [1,705](/filings/0001628280-26-052878.md) |
| Gross margin | % | [83.0%](/filings/0001628280-25-049824.md) | [85.8% d](/filings/0001628280-26-011946.md) | [85.2%](/filings/0001628280-26-030867.md) | [87.5%](/filings/0001628280-26-052878.md) | [86.1%](/filings/0001628280-25-049824.md) | [90.5% d](/filings/0001628280-26-011946.md) | [89.0%](/filings/0001628280-26-030867.md) | [89.8%](/filings/0001628280-26-052878.md) |
| Operating margin | % | [(12.0%)](/filings/0001628280-25-049824.md) | [(7.0%) d](/filings/0001628280-26-011946.md) | [1.0%](/filings/0001628280-26-030867.md) | [6.7%](/filings/0001628280-26-052878.md) | [11.5%](/filings/0001628280-25-049824.md) | [12.4% d](/filings/0001628280-26-011946.md) | [16.5%](/filings/0001628280-26-030867.md) | [19.1%](/filings/0001628280-26-052878.md) |
| Net margin | % | [(12.1%)](/filings/0001628280-25-049824.md) | [(13.5%) d](/filings/0001628280-26-011946.md) | [0.1%](/filings/0001628280-26-052878.md) | [7.2%](/filings/0001628280-26-052878.md) | [8.8%](/filings/0001628280-25-049824.md) | [4.4% d](/filings/0001628280-26-011946.md) | [15.0%](/filings/0001628280-26-052878.md) | [13.9%](/filings/0001628280-26-052878.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001628280-25-049824.md) | not reported | [0.00](/filings/0001628280-26-030867.md) | [0.06](/filings/0001628280-26-052878.md) | [0.08](/filings/0001628280-25-049824.md) | not reported | [0.15](/filings/0001628280-26-030867.md) | [0.16](/filings/0001628280-26-052878.md) |
| Free cash flow | $m | [54.7 d](/filings/0001628280-25-049824.md) | [(17.3) d](/filings/0001628280-26-011946.md) | [(12.3)](/filings/0001628280-26-030867.md) | [220 d](/filings/0001628280-26-052878.md) | [354 d](/filings/0001628280-25-049824.md) | [380 d](/filings/0001628280-26-011946.md) | [161](/filings/0001628280-26-030867.md) | [435 d](/filings/0001628280-26-052878.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,176](/filings/0001651308-24-000014.md) | [1,416](/filings/0001651308-25-000031.md) | [2,459](/filings/0001628280-26-011946.md) | [3,810](/filings/0001628280-26-011946.md) | [5,343](/filings/0001628280-26-011946.md) |
| Gross margin | % | [86.0%](/filings/0001651308-24-000014.md) | [79.8%](/filings/0001651308-25-000031.md) | [84.5%](/filings/0001628280-26-011946.md) | [84.4%](/filings/0001628280-26-011946.md) | [87.5%](/filings/0001628280-26-011946.md) |
| Operating margin | % | [(122.3%)](/filings/0001651308-24-000014.md) | [(126.4%)](/filings/0001651308-25-000031.md) | [(49.1%)](/filings/0001628280-26-011946.md) | [(14.9%)](/filings/0001628280-26-011946.md) | [8.4%](/filings/0001628280-26-011946.md) |
| Net margin | % | [(123.9%)](/filings/0001651308-24-000014.md) | [(141.5%)](/filings/0001651308-25-000031.md) | [(35.9%)](/filings/0001628280-26-011946.md) | [(16.9%)](/filings/0001628280-26-011946.md) | [5.4%](/filings/0001628280-26-011946.md) |
| Diluted EPS | $ per share | [(1.21)](/filings/0001651308-24-000014.md) | [(1.49)](/filings/0001651308-25-000031.md) | [(0.65)](/filings/0001628280-26-011946.md) | [(0.47)](/filings/0001628280-26-011946.md) | [0.19](/filings/0001628280-26-011946.md) |
| Free cash flow | $m | [(1,562)](/filings/0001651308-24-000014.md) | [(1,822)](/filings/0001651308-25-000031.md) | [(1,719)](/filings/0001628280-26-011946.md) | [(633)](/filings/0001628280-26-011946.md) | [942](/filings/0001628280-26-011946.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/onc/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2021-09-10 | [Amgen Inc](/insiders/318154.md) | 10% owner | Purchase (P) | 165,529 | $302.0615 | $50.0m | [Form 4](/filings/0000899243-21-035731.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $2.51bn | 8,801,567 |  | Added +2,514 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $1.43bn | 5,007,931 |  | Added +32,750 |
| [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $1.20bn | 4,210,221 |  | Added +51,495 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $706.3m | 2,478,527 |  | Reduced −1,215,083 |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $641.1m | 2,249,582 |  | Added +626,895 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $406.2m | 1,425,517 |  | Added +393,219 |
| [Temasek Holdings (Private) Ltd](/funds/1021944.md) | 2026-06-30 | $241.0m | 845,729 |  | Reduced −16,914 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $197.9m | 694,618 |  | Added +37,117 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $154.8m | 543,323 |  | Added +338,477 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $141.8m | 497,437 |  | Added +32,965 |

## Recent filings

[All 1,244 filings](/companies/onc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-16 | 16:24 ET | [SCHEDULE 13D/A](/filings/0001104659-26-108269.md) | Ownership report, active investor, amended | 0001104659-26-108269 |
| 2026-08-26 | 06:14 ET | [8-K](/filings/0001651308-26-000025.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001651308-26-000025 |
| 2026-08-05 | 06:04 ET | [10-Q](/filings/0001628280-26-052878.md) | Quarterly report, period 2026-06-30 | 0001628280-26-052878 |
| 2026-08-05 | 06:02 ET | [8-K](/filings/0001628280-26-052877.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-052877 |
| 2026-06-26 | 06:02 ET | [8-K](/filings/0001651308-26-000020.md) | 8.01 Other events | 0001651308-26-000020 |
| 2026-06-15 | 16:40 ET | [SCHEDULE 13D/A](/filings/0001104659-26-074089.md) | Ownership report, active investor, amended | 0001104659-26-074089 |
| 2026-06-11 | 16:13 ET | [8-K](/filings/0001651308-26-000017.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001651308-26-000017 |
| 2026-05-15 | 16:08 ET | [8-K](/filings/0001651308-26-000012.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001651308-26-000012 |
| 2026-05-06 | 06:05 ET | [10-Q](/filings/0001628280-26-030867.md) | Quarterly report, period 2026-03-31 | 0001628280-26-030867 |
| 2026-05-06 | 06:03 ET | [8-K](/filings/0001628280-26-030866.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-030866 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-011946.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/931812d5-d607-4706-b8b4-b581e0687e6a)

## About the filer

- CIK: 1651308
- Tickers: ONC, BEIGF
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:05 ET. No prices; not investment advice.